Scientists hunt for genetic clues in prostate cancer treatment
NCT ID NCT01953640
Summary
This study aims to understand how the genetic makeup of prostate cancer changes when patients take a standard hormone therapy drug (abiraterone acetate). Researchers will collect tissue, blood, and urine samples from 92 men with advanced prostate cancer before and during treatment. By analyzing these samples, they hope to identify genetic markers that can predict how well a patient will respond to therapy and how long the treatment might work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
Conditions
Explore the condition pages connected to this study.